NASDAQ : ESLA
Estrella Immunopharma, Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 0.7287 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 31.70M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 2.70M | 2.81M | 2.44M | 3.20M | 663.19K | 296.25K |
| Research & Development | 6.98M | 10.25M | 6.41M | 4.11M | 10.45M | 1.39M |
| Operating Expenses | 9.68M | 13.06M | 8.85M | 7.31M | 11.11M | 1.69M |
| Operating Income | -9.68M | -13.06M | -8.85M | -7.31M | -11.11M | -1.69M |
| Pretax Income | -10.01M | -13.06M | -8.85M | -7.31M | -11.11M | -1.69M |
| Income Tax Expense | -25.00 | 838.00 | 1.69K | 1.62K | ||
| Net Income | -10.01M | -13.06M | -8.85M | -7.31M | -11.11M | -1.69M |
| Preferred Dividends & Other Adjustments | -611.20K | |||||
| Net Income to Common | -10.01M | -13.06M | -8.85M | -7.31M | -11.11M | -1.07M |
| Shares Outstanding (Basic) | 40.01M | 36.82M | 36.23M | 27.10M | 305.75K | |
| Shares Outstanding (Diluted) | 40.01M | 36.82M | 36.23M | 27.10M | 305.75K | |
| EPS (Basic) | -0.25 | -0.35 | -0.24 | -0.27 | -36.35 | |
| EPS (Diluted) | -0.25 | -0.35 | -0.24 | -0.27 | -36.35 | |
| EBIT | -9.68M | -13.06M | -8.85M | -7.31M | -11.11M | -1.69M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 146.67K | 1.38M | 916.92K | 4.17M | 2.48M | 4.09M |
| Cash & Short-Term Investments | 146.67K | 1.38M | 916.92K | 4.17M | 2.48M | 4.09M |
| Receivables | 273.07K | |||||
| Prepaid Expenses | 1.68M | 292.67K | 723.86K | 288.76K | 833.33K | |
| Total Current Assets | 1.82M | 1.68M | 1.64M | 4.45M | 2.75M | 4.92M |
| Long-Term Deferred Charges | 276.19K | |||||
| Other Long-Term Assets | 1.50M | 1.50M | ||||
| Total Assets | 1.82M | 3.18M | 3.14M | 4.45M | 3.03M | 4.92M |
| Accounts Payable | 8.23K | 554.78K | 4.43K | |||
| Accrued Expenses | 8.56M | 12.61M | 2.98M | 135.61K | 8.85M | 30.02K |
| Current Portion of Leases | 6.00K | 4.00K | 4.00K | 22.00K | ||
| Current Income Taxes Payable | 50.00 | 40.74K | ||||
| Other Current Liabilities | 688.28K | 375.26K | 10.63K | 347.00 | 883.33K | 916.67K |
| Total Current Liabilities | 9.26M | 13.54M | 3.00M | 180.70K | 9.76M | 946.68K |
| Other Long-Term Liabilities | 12.72K | 14.82K | ||||
| Total Liabilities | 9.26M | 13.54M | 3.00M | 180.70K | 9.77M | 961.51K |
| Common Stock | 4.36K | 3.85K | 3.67K | 3.66K | 98.00 | 18.00 |
| Additional Paid-In Capital | 34.75M | 27.22M | 24.64M | 24.12M | 445.90K | 34.29K |
| Retained Earnings | -41.59M | -36.99M | -23.93M | -19.50M | -12.19M | -1.07M |
| Treasury Stock | -598.38K | -598.38K | -568.92K | -354.44K | ||
| Total Common Equity | -7.43M | -10.37M | 143.73K | 4.27M | -11.74M | -1.04M |
| Shareholders' Equity | -7.43M | -10.37M | 143.73K | 4.27M | -6.74M | 3.96M |
| Total Liabilities & Equity | 1.82M | 3.18M | 3.14M | 4.45M | 3.03M | 4.92M |
| Total Debt | 6.00K | 4.00K | 4.00K | 22.00K | ||
| Net Cash (Debt) | 146.67K | 1.38M | 912.92K | 4.16M | 2.46M | 4.09M |
| Net Cash Per Share | 0.00 | 0.04 | 0.03 | 0.15 | 8.04 | |
| Filing Date Shares Outstanding | 43.50M | 42.67M | 36.17M | 36.19M | 35.20M | 176.00K |
| Total Common Shares Outstanding | 43.03M | 37.97M | 36.19M | 36.29M | 4.06M | 176.00K |
| Working Capital | -7.43M | -11.87M | -1.36M | 4.27M | -7.01M | 3.97M |
| Book Value Per Share | -0.17 | -0.27 | 0.00 | 0.12 | -2.89 | -5.91 |
| Tangible Book Value | -7.43M | -10.37M | 143.73K | 4.27M | -11.74M | -1.04M |
| Tangible Book Value Per Share | -0.17 | -0.27 | 0.00 | 0.12 | -2.89 | -5.91 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Net Income | -10.01M | -13.06M | -8.85M | -7.31M | -11.11M | -1.69M |
| Stock-Based Compensation | 592.79K | 618.97K | 432.26K | 1.19M | 409.60K | 129.97K |
| Other Operating Activities | 368.91K | 38.19K | ||||
| Change in Accounts Payable | 78.00 | 550.35K | -72.64K | -9.33M | 8.39M | |
| Change in Income Taxes | -50.00 | -40.69K | ||||
| Change in Other Net Operating Assets | -332.62K | 10.07M | 889.03K | -618.09K | 981.13K | 113.35K |
| Operating Cash Flow | -9.38M | -1.79M | -7.64M | -16.07M | -1.34M | -1.44M |
| Other Investing Activities | 4.96M | -273.07K | ||||
| Investing Cash Flow | 4.96M | -273.07K | ||||
| Short-Term Debt Issued | 300.00K | |||||
| Total Debt Issued | 300.00K | |||||
| Short-Term Debt Repaid | -300.00K | |||||
| Total Debt Repaid | -300.00K | |||||
| Issuance of Common Stock | 9.05M | 2.40M | 79.49K | 10.00M | 15.00K | |
| Repurchase of Common Stock | -29.46K | -568.92K | -5.43M | |||
| Other Financing Activities | -836.36K | -117.47K | -798.67K | 515.36K | ||
| Financing Cash Flow | 8.21M | 2.25M | -489.43K | 12.79M | 5.53M | |
| Net Cash Flow | -1.17M | 467.39K | -8.13M | 1.69M | -1.61M | 4.09M |
| Levered Free Cash Flow | -6.79M | 3.43M | -12.95M | 2.81M | ||
| Unlevered Free Cash Flow | -6.79M | 3.43M | -12.95M | 2.81M | ||
| Cash Interest Paid | 2.66K | |||||
| Cash Income Tax Paid | 1.60K | 913.00 | 43.97K | 1.60K | ||
| Change in Working Capital | -332.54K | 10.62M | 775.70K | -9.95M | 9.37M | 113.35K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 18.54M | 58.91M | 43.41M | 38.20M | 18.98M | |
| Enterprise Value | 18.40M | 57.29M | 41.62M | 33.47M | 21.37M | |
| Last Close Price | 0.64 | 1.56 | 1.20 | 1.05 | 10.84 | 10.00 |
| PB Ratio | -5.68 | 302.06 | 8.94 | -2.81 | ||
| P/TBV Ratio | 302.06 | 8.94 | ||||
| Debt / Equity Ratio | -0.00 | 0.03 | 0.00 | -0.00 | ||
| Net Debt / Equity Ratio | 0.02 | 0.13 | -6.35 | -0.97 | 0.36 | -1.03 |
| Quick Ratio | 0.02 | 0.10 | 0.31 | 23.05 | 0.25 | 4.32 |
| Current Ratio | 0.20 | 0.12 | 0.55 | 24.65 | 0.28 | 5.20 |
| Return on Assets (ROA) | -251.86% | -258.45% | -122.12% | -174.75% | ||
| Return on Capital Employed (ROCE) | 130.30% | 126.00% | -6,154.50% | -171.10% | 165.20% | -42.40% |
| Earnings Yield | -58.70% | -22.17% | -20.38% | -19.14% | -58.56% | |
| Buyback Yield / Dilution | -10.44% | -1.63% | -33.68% | -8,764.81% |